SNGX - Soligenix surges on favorable preclinical work of its COVID-19 vaccine

Soligenix, Inc. (SNGX) has added ~13.7% in the pre-market after announcing the publication of pre-clinical immunogenicity studies for CiVax, the company’s heat-stable vaccine candidate for the prevention of COVID-19.According to the company, the article posted as an accelerated preprint on bioRxiv indicates the studies to confirm the rapid-onset, broad-spectrum, neutralizing antibody, and cell-mediated immunity achieved using the full-length Spike protein antigens confirms.The latest results show the immunogenic potential of the full-length CiVax™ antigen in combination with CoVaccine HT, specifically in the context of SARS-CoV-2, Soligenix added.The company’s previous work CoVaccine HT adjuvant, which was licensed by Soligenix from BTG Specialty Pharmaceuticals, a division of Boston Scientific, has indicated that the adjuvant can be thermostabilized both alone and in combination with antigens.That will potentially lead to the development of a single vial of the vaccine with no requirement for cold chain distribution or storage.   “We are very encouraged with the latest results and look forward to continuing

For further details see:

Soligenix surges on favorable preclinical work of its COVID-19 vaccine